The influence of GSTT/GSTM null genotypes in scarring.

genotype glutathione S-transferase M1 glutathione S-transferase T1 scarring

Journal

Medicine and pharmacy reports
ISSN: 2668-0572
Titre abrégé: Med Pharm Rep
Pays: Romania
ID NLM: 101742144

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 05 07 2019
revised: 06 09 2019
accepted: 27 09 2019
entrez: 29 1 2020
pubmed: 29 1 2020
medline: 29 1 2020
Statut: ppublish

Résumé

The process of scarring is a common denominator of interest for the medical field. From general medicine to dentistry, pathological scar tissue represents a challenge in providing optimal care to a patient. The present study aims to investigate whether a systemically reduced antioxidant potential, revealed by null isoforms of glutathione S transferase, affects the process of scarring in a group of female patients. The study is based on a group of 54 patients with physiological scars after a 6-month observation period, as well as 18 patients with hypertrophic or atrophic scars. Peripheral venous blood was collected, from which DNA was extracted using a commercial kit. Genotyping followed a Multiplex PCR protocol for GSTT1/GSTM1. In a dominant model, the combination of wild type (heterozygous or homozygous) GSTT1 and GSTM1 was negatively associated with pathological scarring, with the wild type (heterozygous or homozygous) GSTM1 genotype being potentially responsible for this effect. Other factors affecting pathological scarring were investigated: family history, phototype, as well as scores on the POSAS and SCAR scales. The presence of GSTT1 and GSTM1 alleles brings forward an increased antioxidant capacity, serving as a protective factor for patients during scar formation.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The process of scarring is a common denominator of interest for the medical field. From general medicine to dentistry, pathological scar tissue represents a challenge in providing optimal care to a patient. The present study aims to investigate whether a systemically reduced antioxidant potential, revealed by null isoforms of glutathione S transferase, affects the process of scarring in a group of female patients.
METHODS METHODS
The study is based on a group of 54 patients with physiological scars after a 6-month observation period, as well as 18 patients with hypertrophic or atrophic scars. Peripheral venous blood was collected, from which DNA was extracted using a commercial kit. Genotyping followed a Multiplex PCR protocol for GSTT1/GSTM1.
RESULTS RESULTS
In a dominant model, the combination of wild type (heterozygous or homozygous) GSTT1 and GSTM1 was negatively associated with pathological scarring, with the wild type (heterozygous or homozygous) GSTM1 genotype being potentially responsible for this effect. Other factors affecting pathological scarring were investigated: family history, phototype, as well as scores on the POSAS and SCAR scales.
CONCLUSIONS CONCLUSIONS
The presence of GSTT1 and GSTM1 alleles brings forward an increased antioxidant capacity, serving as a protective factor for patients during scar formation.

Identifiants

pubmed: 31989113
doi: 10.15386/mpr-1513
pii: cm-92-s73
pmc: PMC6978933
doi:

Types de publication

Journal Article

Langues

eng

Pagination

S73-S77

Références

Adv Wound Care (New Rochelle). 2018 Feb 1;7(2):29-45
pubmed: 29392092
Indian J Dermatol Venereol Leprol. 2018 Jan-Feb;84(1):39-44
pubmed: 29067933
J Am Coll Clin Wound Spec. 2016 Nov 30;7(1-3):1-7
pubmed: 28053861
PLoS One. 2012;7(12):e50229
pubmed: 23226515
PLoS One. 2015 May 04;10(5):e0125295
pubmed: 25938472
Pharmacogenet Genomics. 2011 Apr;21(4):217-24
pubmed: 20802377
J Surg Res. 1999 Dec;87(2):209-16
pubmed: 10600351
J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2112-9
pubmed: 25866177
Clujul Med. 2015;88(2):159-63
pubmed: 26528065
J Psychosom Res. 2012 Apr;72(4):282-7
pubmed: 22405222

Auteurs

Roxana Flavia Ilieş (RF)

Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj- Napoca, Romania.

Andreea Cătană (A)

Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj- Napoca, Romania.
Ion Chiricuţă Oncological Institute, Cluj-Napoca, Romania.

Radu Popp (R)

Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj- Napoca, Romania.

Casian Simon Aioanei (CS)

Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj- Napoca, Romania.

Salomea-Ruth Halmagyi (SR)

Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj- Napoca, Romania.

Istvan Lukacs (I)

1 Department of Obstetrics and Gynecology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania.

Reka-Eniko Tokes (RE)

1 Department of Obstetrics and Gynecology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania.

Ioana Cristina Rotar (IC)

1 Department of Obstetrics and Gynecology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Romania.

Ioan Victor Pop (IV)

Department of Medical Genetics, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj- Napoca, Romania.

Classifications MeSH